AMP-activated protein kinase activation mediates CCL3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma. 2013

Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
Graduate Institute of Basic Medical Science, China Medical University, No, 91, Hsueh-Shih Road, Taichung, Taiwan. chtang@mail.cmu.edu.tw.

Chemokine (C-C motif) ligand 3 (CCL3), also known as macrophage inflammatory protein-1α, is a cytokine involved in inflammation and activation of polymorphonuclear leukocytes. CCL3 has been detected in infiltrating cells and tumor cells. Chondrosarcoma is a highly malignant tumor that causes distant metastasis. However, the effect of CCL3 on human chondrosarcoma metastasis is still unknown. Here, we found that CCL3 increased cellular migration and expression of matrix metalloproteinase (MMP)-2 in human chondrosarcoma cells. Pre-treatment of cells with the MMP-2 inhibitor or transfection with MMP-2 specific siRNA abolished CCL3-induced cell migration. CCL3 has been reported to exert its effects through activation of its specific receptor, CC chemokine receptor 5 (CCR5). The CCR5 and AMP-activated protein kinase (AMPK) inhibitor or siRNA also attenuated CCL3-upregulated cell motility and MMP-2 expression. CCL3-induced expression of MMP-2 and migration were also inhibited by specific inhibitors, and inactive mutants of AMPK, p38 mitogen activated protein kinase (p38 or p38-MAPK), and nuclear factor κB (NF-κB) cascades. On the other hand, CCL3 treatment demonstrably activated AMPK, p38, and NF-κB signaling pathways. Furthermore, the expression levels of CCL3, CCR5, and MMP-2 were correlated in human chondrosarcoma specimens. Taken together, our results indicate that CCL3 enhances the migratory ability of human chondrosarcoma cells by increasing MMP-2 expression via the CCR5, AMPK, p38, and NF-κB pathways.

UI MeSH Term Description Entries
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002813 Chondrosarcoma A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed) Chondrosarcomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D048051 p38 Mitogen-Activated Protein Kinases A mitogen-activated protein kinase subfamily that regulates a variety of cellular processes including CELL GROWTH PROCESSES; CELL DIFFERENTIATION; APOPTOSIS; and cellular responses to INFLAMMATION. The P38 MAP kinases are regulated by CYTOKINE RECEPTORS and can be activated in response to bacterial pathogens. Mitogen-Activated Protein Kinase p38,p38 Mitogen-Activated Protein Kinase,p38 MAP Kinase,p38 MAPK,p38 Protein Kinase,p38 SAPK,MAP Kinase, p38,MAPK, p38,Mitogen Activated Protein Kinase p38,Protein Kinase, p38,p38 Mitogen Activated Protein Kinase,p38 Mitogen Activated Protein Kinases
D054405 Chemokine CCL3 A CC chemokine with specificity for CCR1 RECEPTORS and CCR5 RECEPTORS. It is a chemoattractant for NK CELLS; MONOCYTES; and a variety of other immune cells. This chemokine is encoded by multiple genes. CCL3 Chemokine,CCL3L1 Chemokine,CCL3L2 Chemokine,CCL3L3 Chemokine,Chemokine CCL3L1,Chemokine CCL3L2,Chemokine CCL3L3,BB-10010,Chemokine (C-C Motif) Ligand 3,Chemokine (C-C Motif) Ligand 3-Like 1,Chemokine (C-C Motif) Ligand 3-Like 2,LD78alpha Chemokine,LD78beta Chemokine,MIP-1alpha,Macrophage Inflammatory Protein 1-alpha,Small Inducible Cytokine A3,BB 10010,BB10010,CCL3, Chemokine,CCL3L1, Chemokine,CCL3L2, Chemokine,CCL3L3, Chemokine,Chemokine, CCL3,Chemokine, CCL3L1,Chemokine, CCL3L2,Chemokine, CCL3L3,Chemokine, LD78alpha,Chemokine, LD78beta,Macrophage Inflammatory Protein 1 alpha
D055372 AMP-Activated Protein Kinases Intracellular signaling protein kinases that play a signaling role in the regulation of cellular energy metabolism. Their activity largely depends upon the concentration of cellular AMP which is increased under conditions of low energy or metabolic stress. AMP-activated protein kinases modify enzymes involved in LIPID METABOLISM, which in turn provide substrates needed to convert AMP into ATP. 5'-AMP-Activated Protein Kinase,AMP-Activated Kinase,AMP-Activated Protein Kinase,AMP-Activated Protein Kinase alpha Subunit,AMP-Activated Protein Kinase alpha Subunits,AMP-Activated Protein Kinase beta Subunit,AMP-Activated Protein Kinase beta Subunits,AMP-Activated Protein Kinase gamma Subunit,AMP-Activated Protein Kinase gamma Subunits,PRKAA,5' AMP Activated Protein Kinase,AMP Activated Kinase,AMP Activated Protein Kinase,AMP Activated Protein Kinase alpha Subunit,AMP Activated Protein Kinase alpha Subunits,AMP Activated Protein Kinase beta Subunit,AMP Activated Protein Kinase beta Subunits,AMP Activated Protein Kinase gamma Subunit,AMP Activated Protein Kinase gamma Subunits,AMP Activated Protein Kinases
D019713 Receptors, CCR5 CCR receptors with specificity for CHEMOKINE CCL3; CHEMOKINE CCL4; and CHEMOKINE CCL5. They are expressed at high levels in T-LYMPHOCYTES; B-LYMPHOCYTES; MACROPHAGES; MAST CELLS; and NK CELLS. The CCR5 receptor is used by the HUMAN IMMUNODEFICIENCY VIRUS to infect cells. Antigens, CD195,CC Chemokine Receptor 5,CCR5 Receptors,CD195 Antigens,CC-CKR5,CCR5 Receptor,CKR5 Receptors,Receptors, CKR5,Receptor, CCR5

Related Publications

Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
May 2011, The Journal of biological chemistry,
Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
June 2012, Cellular signalling,
Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
August 2012, Journal of cellular physiology,
Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
October 1997, Journal of cell science,
Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
November 2017, American journal of rhinology & allergy,
Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
December 2013, Cellular signalling,
Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
March 2005, Proceedings of the National Academy of Sciences of the United States of America,
Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
December 1998, The Biochemical journal,
Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
February 2004, Cancer research,
Chin-Jung Hsu, and Min-Huan Wu, and Chin-Yuan Chen, and Chun-Hao Tsai, and Horng-Chaung Hsu, and Chih-Hsin Tang
September 2018, Molecules (Basel, Switzerland),
Copied contents to your clipboard!